Filing Flows › Core Scientific, Inc./tx (CORZ) › Q3 2026 › vs Q3 2025
Core Scientific, Inc./tx (CORZ) Q3 2026 vs Q3 2025 (year over year)
Core Scientific, Inc./tx's revenue rose $152M (+187%) from $81.1M in Q3 2025 to $233M in Q3 2026. Gross margin 52.9% against 4.8% (+48.1 pts).
Core Scientific, Inc./tx, Q3 2026: revenue $233M (+187% year over year), operating margin 31.1%, net earnings $1.2B, operating cash flow $65.3M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 52.9% | 4.8% | +48.1 pts |
| Operating margin | 31.1% | -67.6% | +98.6 pts |
| Net margin | 505.9% | -177.6% | +683.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $233M | $81.1M | $152M | +187% |
| Gross profit | $123M | $3.9M | $119M | 32× |
| Cost of revenue | $110M | $77.2M | $32.4M | +42% |
| Other income, net | $999M | −$89.1M | $1.1B | — |
| Operating profit | $72.3M | −$54.8M | $127M | — |
| Operating expenses | $50.9M | $58.7M | −$7.8M | -13% |
| Pre-tax earnings | $1.1B | −$144M | $1.2B | — |
| Income tax benefit | $107M | −$125K | $107M | — |
| Net earnings | $1.2B | −$144M | $1.3B | — |
| Depreciation & amortization | $18.0M | $16.3M | $1.7M | +10% |
| Share-based compensation | $25.2M | $29.9M | −$4.8M | -16% |
| Working capital & other | $1.2B | −$230M | $1.4B | — |
| Operating cash flow | $65.3M | $132M | −$66.5M | -50% |
| Capital expenditures | $541M | $244M | $296M | +121% |
| Negative free cash flow (OCF − capex) | $475M | $113M | $363M | +322% |
Questions
How much did Core Scientific, Inc./tx's revenue grow year over year in Q3 2026?
Core Scientific, Inc./tx's revenue rose $152M (+187%) from $81.1M in Q3 2025 to $233M in Q3 2026. Gross margin 52.9% against 4.8% (+48.1 pts).